Modulation of human leukocyte antigen-C by human cytomegalovirus stimulates KIR2DS1 recognition by natural killer cells

Frontiers in Immunology

Volumn 8, Issue MAR, 2017, Pages

  van der Ploeg, Kattria ^a   Chang, Chiwen ^a   Ivarsson, Martin A ^a   Moffett, Ashley ^a   Wills, Mark R ^a   Trowsdale, John ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

HLA C; Human cytomegalovirus; Killer Ig like receptor; KIR2DS1; Natural killer cells

Indexed keywords

BLOCKING ANTIBODY; CASPASE 9; CRISPR ASSOCIATED PROTEIN; GAMMA INTERFERON; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ANTIGEN RECOGNITION; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL GROWTH; CELL INTERACTION; CELL ISOLATION; CONTROLLED STUDY; CROSS LINKING; CYTOMEGALOVIRUS; FLOW CYTOMETRY; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE CELL FUNCTION ASSAY; IMMUNOFLUORESCENCE TEST; IMMUNOMODULATION; NATURAL KILLER CELL; PLAQUE ASSAY; PROTEIN EXPRESSION; PROTEIN INTERACTION; VIRUS INFECTION; WESTERN BLOTTING;

EID: 85017189025     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00298     Document Type: Article

References (92)

1. Kiessling R, Klein E, Wigzell H. 'Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol (1975) 5(2):112-7. doi:10.1002/eji.1830050208
2. Kiessling R, Klein E, Pross H, Wigzell H. 'Natural' killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol (1975) 5(2):117-21. doi:10.1002/eji.1830050209
3. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer (1975) 16(2):216-29. doi:10.1002/ijc.2910160204
4. Carrington M, Norman P. The KIR Gene Cluster. Bookshelf NCBI. Bethesda (MD): National Center for Biotechnology Information (2003). Bookshelf ID: NBK45311
5. Fan QR, Long EO, Wiley DC. Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat Immunol (2001) 2(5):452-60. doi:10.1038/87766
6. Snyder GA, Brooks AG, Sun PD. Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2. Proc Natl Acad Sci U S A (1999) 96(7):3864-9. doi:10.1073/pnas.96.7.3864
7. Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol (1998) 161(2):571-7
8. Moesta AK, Parham P. Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3. Front Immunol (2012) 3:1-13. doi:10.3389/fimmu.2012.00336
9. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol (2008) 180(6):3969-79. doi:10.4049/jimmunol.180.6.3969
10. David G, Djaoud Z, Willem C, Legrand N, Rettman P, Gagne K, et al. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 specificity of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation. J Immunol (2013) 191(9):4778-88. doi:10.4049/jimmunol.1301580
11. Hilton HG, Guethlein LA, Goyos A, Nemat-Gorgani N, Bushnell DA, Norman PJ, et al. Polymorphic HLA-C receptors balance the functional characteristics of KIR haplotypes. J Immunol (2015) 195:3160-70. doi:10.4049/jimmunol.1501358
12. Biassoni R, Cantoni C, Falco M, Verdiani S, Bottino C, Vitale M, et al. The human leukocyte antigen (HLA)-C-specific 'activatory' or 'inhibitory' natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J Exp Med (1996) 183(2):645-50. doi:10.1084/jem.183.2.645
13. Akkaya M, Barclay AN. How do pathogens drive the evolution of paired receptors? Eur J Immunol (2013) 43(2):303-13. doi:10.1002/eji.201242896
14. Ivarsson MA, Michaëlsson J, Fauriat C. Activating killer cell Ig-like receptors in health and disease. Front Immunol (2014) 5:1-9. doi:10.3389/fimmu.2014.00184
15. Abi-Rached L, Parham P. Natural selection drives recurrent formation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues. J Exp Med (2005) 201(8):1319-32. doi:10.1084/jem.20042558
16. Barclay AN, Hatherley D. The counterbalance theory for evolution and function of paired receptors. Immunity (2008) 29(5):675-8. doi:10.1016/j.immuni.2008.10.004
17. Moesta AK, Graef T, Abi-Rached L, Older Aguilar AM, Guethlein LA, Parham P. Humans differ from other hominids in lacking an activating NK cell receptor that recognizes the C1 epitope of MHC class I. J Immunol (2010) 185(7):4233-7. doi:10.4049/jimmunol.1001951
18. Liu J, Xiao Z, Ko HL, Shen M, Ren EC. Activating killer cell immunoglobulin-like receptor 2DS2 binds to HLA-A*11. Proc Natl Acad Sci U S A (2014) 111(7):2662-7. doi:10.1073/pnas.1322052111
19. Valés-Gómez M, Reyburn HT, Erskine RA, Strominger J. Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc Natl Acad Sci U S A (1998) 95(24):14326-31. doi:10.1073/pnas.95.24.14326
20. Campbell KS, Cella M, Carretero M, López-Botet M, Colonna M. Signaling through human killer cell activating receptors triggers tyrosine phosphorylation of an associated protein complex. Eur J Immunol (1998) 28(2):599-609. doi:10.1002/(SICI)1521-4141(199802)28:02<599:AID-IMMU599>3.0.CO;2-F
21. Katz G, Gazit R, Arnon TI, Gonen-Gross T, Tarcic G, Markel G, et al. MHC class I-independent recognition of NK-activating receptor KIR2DS4. J Immunol (2004) 173(3):1819-25. doi:10.4049/jimmunol.173.3.1819
22. Graef T, Moesta AK, Norman PJ, Abi-Rached L, Vago L, Older Aguilar AM, et al. KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. J Exp Med (2009) 206(11):2557-72. doi:10.1084/jem.20091010
23. VandenBussche CJ, Mulrooney TJ, Frazier WR, Dakshanamurthy S, Hurley CK. Dramatically reduced surface expression of NK cell receptor KIR2DS3 is attributed to multiple residues throughout the molecule. Genes Immun (2009) 10(2):162-73. doi:10.1038/gene.2008.91
24. Moretta A, Sivori S, Vitale M, Pende D, Morelli L, Augugliaro R, et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med (1995) 182(3):875-84. doi:10.1084/jem.182.3.875
25. Biassoni R, Pessino A, Malaspina A, Cantoni C, Bottino C, Sivori S, et al. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur J Immunol (1997) 27(12):3095-9. doi:10.1002/eji.1830271203
26. Mandelboim O, Kent S, Davis DM, Wilson SB, Okazaki T, Jackson R, et al. Natural killer activating receptors trigger interferon secretion from T cells and natural killer cells. Proc Natl Acad Sci U S A (1998) 95(7):3798-803. doi:10.1073/pnas.95.7.3798
27. Stewart CA, Laugier-Anfossi F, Vély F, Saulquin X, Riedmuller J, Tisserant A, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A (2005) 102(37):13224-9. doi:10.1073/pnas.0503594102
28. Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol (2007) 179(2):854-68. doi:10.4049/jimmunol.179.2.854
29. Morvan M, David G, Sébille V, Perrin A, Gagne K, Willem C, et al. Autologous and allogeneic HLA KIR ligand environments and activating KIR control KIR NK-cell functions. Eur J Immunol (2008) 38(12):3474-86. doi:10.1002/eji.200838407
30. Foley B, De Santis D, Lathbury L, Christiansen F, Witt C. KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals. Int Immunol (2008) 20(4):555-63. doi:10.1093/intimm/dxn013
31. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood (2009) 113(13):3119-29. doi:10.1182/blood-2008-06-164103
32. Fauriat C, Ivarsson MA, Ljunggren HG, Malmberg KJ, Michaëlsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood (2010) 115(6):1166-74. doi:10.1182/blood-2009-09-245746
33. Sivori S, Carlomagno S, Falco M, Romeo E, Moretta L, Moretta A. Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood (2011) 117(16):4284-92. doi:10.1182/blood-2010-10-316125
34. Xiong S, Sharkey AM, Kennedy PR, Gardner L, Farrell LE, Chazara O, et al. Maternal uterine NK cell-activating receptor KIR2DS1 enhances placentation. J Clin Invest (2013) 123(10):4264-72. doi:10.1172/JCI68991
35. Pittari G, Liu XR, Selvakumar A, Zhao Z, Merino E, Huse M, et al. NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand. J Immunol (2013) 190(9):4650-60. doi:10.4049/jimmunol.1202120
36. Cassidy SA, Cheent KS, Khakoo SI. Effects of peptide on NK cell-mediated MHC I recognition. Front Immunol (2014) 5:133. doi:10.3389/fimmu.2014.00133
37. Das J, Khakoo SI. NK cells: tuned by peptide? Immunol Rev (2015) 267(1):214-27. doi:10.1111/imr.12315
38. Salzberger W, Garcia-Beltran WF, Dugan H, Gubbala S, Simoneau C, Gressens SB, et al. Influence of glycosylation inhibition on the binding of KIR3DL1 to HLA-B*57:01. PLoS One (2015) 10(12):1-14. doi:10.1371/journal.pone.0145324
39. Steiner NK, Dakshanamurthy S, Nguyen N, Hurley CK. Allelic variation of killer cell immunoglobulin-like receptor 2DS5 impacts glycosylation altering cell surface expression levels. Hum Immunol (2014) 75(2):124-8. doi:10.1016/j.humimm.2013.11.012
40. Kollnberger S, Chan A, Sun MY, Chen LY, Wright C, di Gleria K, et al. Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide. Eur J Immunol (2007) 37(5):1313-22. doi:10.1002/eji.200635997
41. Garcia-Beltran WF, Hölzemer A, Martrus G, Chung AW, Pacheco Y, Simoneau CR, et al. Open conformers of HLA-F are high-affinity ligands of the activating NK-cell receptor KIR3DS1. Nat Immunol (2016) 17(9):1067-74. doi:10.1038/ni.3513
42. Burian A, Wang KL, Finton KAK, Lee N, Ishitani A, Strong K, et al. HLA-F and MHC-I open conformers bind natural killer cell Ig-like receptor KIR3DS1. PLoS One (2016) 11(9):e0163297. doi:10.1371/journal.pone.0163297
43. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science (2002) 296(5571):1323-6. doi:10.1126/science.1070884
44. Béziat V, Liu LL, Malmberg J-A, Ivarsson MA, Sohlberg E, Björklund AT, et al. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood (2013) 121(14):2678-88. doi:10.1182/blood-2012-10-459545
45. Della Chiesa M, Falco M, Bertaina A, Muccio L, Alicata C, Frassoni F, et al. Human cytomegalovirus infection promotes rapid maturation of NK cells expressing activating killer Ig-like receptor in patients transplanted with NKG2C-/-umbilical cord blood. J Immunol (2014) 192(4):1471-9. doi:10.4049/jimmunol.1302053
46. Charoudeh HN, Terszowski G, Czaja K, Gonzalez A, Schmitter K, Stern M. Modulation of the natural killer cell KIR repertoire by cytomegalovirus infection. Eur J Immunol (2013) 43(2):480-7. doi:10.1002/eji.201242389
47. Crespo âC, Strominger JL, Tilburgs T. Expression of KIR2DS1 by decidual natural killer cells increases their ability to control placental HCMV infection. Proc Natl Acad Sci U S A (2016) 113(52):15072-7. doi:10.1073/pnas.1617927114
48. Ehrhardt C, Schmolke M, Matzke A, Knoblauch A, Will C, Wixler V, et al. Polyethylenimine, a cost-effective transfection reagent. Signal Transduct (2006) 6(3):179-84. doi:10.1002/sita.200500073
49. Baía D, Pou J, Jones DC, Mandelboim O, Trowsdale J, Muntasell A, et al. Interaction of the LILRB1 inhibitory receptor with HLA class Ia dimers. Eur J Immunol (2016) 46(7):1681-90. doi:10.1002/eji.201546149
50. Tran T, Ivanyi P, Hilgert I, Brdicka T, Pla M, Breur B, et al. The epitope recognized by pan-HLA class I-reactive monoclonal antibody W6/32 and its relationship to unusual stability of the HLA-B27/β2-microglobulin complex. Immunogenetics (2001) 53(6):440-6. doi:10.1007/s002510100353
51. Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell (1978) 14(1):9-20. doi:10.1016/0092-8674(78)90296-9
52. Rebaï N, Malissen B. Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies. Tissue Antigens (2008) 22(2):107-17. doi:10.1111/j.1399-0039.1983.tb01176.x
53. Ciccone E, Pende D, Nanni L, Di Donato C, Viale O, Beretta A, et al. General role of HLA class I molecules in the protection of target cells from lysis by natural killer cells: evidence that the free heavy chains of class I molecules are not sufficient to mediate the protective effect. Int Immunol (1995) 7(3):393-400. doi:10.1093/intimm/7.3.393
54. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol (1986) 137(7):2299-306
55. Sernee MF, Ploegh HL, Schust DJ. Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol (1998) 35(3):177-88. doi:10.1016/S0161-5890(98)00026-1
56. Braud VM, Allan DS, Wilson D, McMichael AJ. TAP-and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol (1998) 8(1):1-10. doi:10.1016/S0960-9822(98)70014-4
57. Setini A, Beretta A, De Santis C, Meneveri R, Martayan A, Mazzilli MC, et al. Distinctive features of the a1-domain alpha helix of HLA-C heavy chains free of β2-microglobulin. Hum Immunol (1996) 46(2):69-81. doi:10.1016/0198-8859(96)00011-0
58. Bryceson YT, Fauriat C, Nunes JM, Wood SM, Björkström NK, Long EO, et al. Functional analysis of human NK cells by flow cytometry. Methods Mol Biol (2010) 612:335-52. doi:10.1007/978-1-60761-362-6_23
59. Sinzger C, Schmidt K, Knapp J, Kahl M, Beck R, Waldman J, et al. Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome. J Gen Virol (1999) 80(11):2867-77. doi:10.1099/0022-1317-80-11-2867
60. Wills MR, Ashiru O, Reeves MB, Okecha G, Trowsdale J, Tomasec P, et al. Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. J Immunol (2005) 175(11):7457-65. doi:10.4049/jimmunol.175.11.7457
61. Stinski MF. Sequence of protein synthesis in cells infected by human cytomegalovirus: early and late virus-induced polypeptides. J Virol (1978) 26(3):686-701
62. Haan C, Behrmann I. A cost effective non-commercial ECL-solution for western blot detections yielding strong signals and low background. J Immunol Methods (2007) 318(1-2):11-9. doi:10.1016/j.jim.2006.07.027
63. Koike-Yusa H, Li Y, Tan EP, Velasco-Herrera Mdel C, Yusa K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol (2013) 32(3):267-73. doi:10.1038/nbt.2800
64. Jones DC, Kosmoliaptsis V, Apps R, Lapaque N, Smith I, Kono A, et al. HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding. J Immunol (2011) 186(5):2990-7. doi:10.4049/jimmunol.1003078
65. Sinzger C, Grefte A, Plachter B, Gouw AS, The TH, Jahn G. Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. J Gen Virol (1995) 76(4):741-50. doi:10.1099/0022-1317-76-4-741
66. Ahn K, Angulo A, Ghazal P, Peterson PA, Yang Y, Früh K. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci U S A (1996) 93(20):10990-5. doi:10.1073/pnas.93.20.10990
67. Noriega VM, Tortorella D. Human cytomegalovirus-encoded immune modulators partner to downregulate major histocompatibility complex class I molecules. J Virol (2009) 83(3):1359-67. doi:10.1128/JVI.01324-08
68. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell (1996) 84(5):769-79. doi:10.1016/S0092-8674(00)81054-5
69. Jones TR, Sun L. Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. J Virol (1997) 71(4):2970-9
70. Ahn K, Gruhler A, Galocha B, Jones TR, Wiertz EJ, Ploegh HL, et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity (1997) 6(5):613-21. doi:10.1016/S1074-7613(00)80349-0
71. Lehner PJ, Karttunen JT, Wilkinson GWG, Cresswell P. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc Natl Acad Sci U S A (1997) 94(13):6904-9. doi:10.1073/pnas.94.13.6904
72. Cerboni C, Achour A, Wärnmark A, Mousavi-Jazi M, Sandalova T, Hsu ML, et al. Spontaneous mutations in the human CMV HLA class I homologue UL18 affect its binding to the inhibitory receptor LIR-1/ILT2/CD85j. Eur J Immunol (2006) 36(3):732-41. doi:10.1002/eji.200425220
73. Prod'homme V, Griffin C, Aicheler RJ, Wang EC, McSharry BP, Rickards CR, et al. The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1-NK cells. J Immunol (2007) 178(7):4473-81. doi:10.4049/jimmunol.178.7.4473
74. Tomasec P, Wang EC, Davison AJ, Vojtesek B, Armstrong M, Griffin C, et al. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol (2005) 6(2):181-8. doi:10.1038/ni1156
75. Fitzgerald-Bocarsly P. Human natural interferon-a producing cells. Pharmacol Ther (1993) 60(1):39-62. doi:10.1016/0163-7258(93)90021-5
76. Van Damme J, Schaafsma MR, Fibbe WE, Falkenburg JH, Opdenakker G, Billiau A. Simultaneous production of interleukin 6, interferon-β and colony-stimulating activity by fibroblasts after viral and bacterial infection. Eur J Immunol (1989) 19(1):163-8. doi:10.1002/eji.1830190126
77. Magri G, Muntasell A, Romo N, Sáez-Borderías A, Pende D, Geraghty DE, et al. NKp46 and DNAM-1 NK cell receptors drive the response to human cytomegalovirus infected myeloid dendritic cells overcoming viral immune evasion strategies. Blood (2011) 117(3):848-56. doi:10.1182/blood-2010-08-301374
78. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol (2013) 31:443-73. doi:10.1146/annurev-immunol-032712-095910
79. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc (2013) 8(11):2281-308. doi:10.1038/nprot.2013.143
80. Oszmiana A, Williamson DJ, Cordoba SP, Morgan DJ, Kennedy PR, Stacey K, et al. The size of activating and inhibitory killer Ig-like receptor nanoclusters is controlled by the transmembrane sequence and affects signaling. Cell Rep (2016) 15(9):1957-72. doi:10.1016/j.celrep.2016.04.075
81. Bryceson YT, March ME, Ljunggren H-G, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood (2006) 107(1):159-66. doi:10.1182/blood-2005-04-1351
82. Fadda L, Borhis G, Ahmed P, Cheent K, Pageon SV, Cazaly A, et al. Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci U S A (2010) 107(22):10160-5. doi:10.1073/pnas.0913745107
83. Barber LD, Patel TP, Percival L, Gumperz JE, Lanier LL, Phillips JH, et al. Unusual uniformity of the N-linked oligosaccharides of HLA-A,-B, and-C glycoproteins. J Immunol (1996) 156(9):3275-84
84. Tardif KD, Siddiqui A. Cell surface expression of major histocompatibility complex class I molecules is reduced in hepatitis C virus subgenomic replicon-expressing cells. J Virol (2003) 77(21):11644-50. doi:10.1128/JVI.77.21.11644-11650.2003
85. Lantéri M, Giordanengo V, Hiraoka N, Fuzibet JG, Auberger P, Fukuda M, et al. Altered T cell surface glycosylation in HIV-1 infection results in increased susceptibility to galectin-1-induced cell death. Glycobiology (2003) 13(12):909-18. doi:10.1093/glycob/cwg110
86. Kollnberger S, Bird L, Sun MY, Retiere C, Braud VM, McMichael A, et al. Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum (2002) 46(11):2972-82. doi:10.1002/art.10605
87. Kielczewska A, Pyzik M, Sun T, Krmpotic A, Lodoen MB, Munks MW, et al. Ly49P recognition of cytomegalovirus-infected cells expressing H2-Dk and CMV-encoded m04 correlates with the NK cell antiviral response. J Exp Med (2009) 206(3):515-23. doi:10.1084/jem.20080954
88. Serena M, Parolini F, Biswas P, Sironi F, Blanco Miranda A, Zoratti E, et al. HIV-1 env associates with HLA-C free-chains at the cell membrane modulating viral infectivity. Sci Rep (2017) 7:40037. doi:10.1038/srep40037
89. Ameres S, Besold K, Plachter B, Moosmann A. CD8 T cell-evasive functions of human cytomegalovirus display pervasive MHC allele specificity, complementarity, and cooperativity. J Immunol (2014) 192(12):5894-905. doi:10.4049/jimmunol.1302281
90. Ameres S, Mautner J, Schlott F, Neuenhahn M, Busch DH, Plachter B, et al. Presentation of an immunodominant immediate-early CD8+ T cell epitope resists human cytomegalovirus immunoevasion. PLoS Pathog (2013) 9(5):e1003383. doi:10.1371/journal.ppat.1003383
91. Arase H, Lanier LL. Virus-driven evolution of natural killer cell receptors. Microbes Infect (2002) 4(15):1505-12. doi:10.1016/S1286-4579(02)00033-3
92. Chen KC, Stanton RJ, Banat JJ, Wills MR. Leukocyte immunoglobulin-like receptor 1-expressing human natural killer cell subsets differentially recognize isolates of human cytomegalovirus through the viral major histocompatibility complex class I homolog UL18. J Virol (2016) 90(6):3123-37. doi:10.1128/JVI.02614-15